3Brain AG has recently announced a new technology that combines both microchips and artificial intelligence. The revolutionary duo holds the promise of changing the way drug candidates are selected on a preclinical level. This will enhance their chances of maximizing their success.

Preclinical studies are deemed as the most vital for the proper and early identification of safety and efficacy issues. Despite the several improvements made in the area of drug delivery, it often fails because of limited drawbacks in preclinical tests on animal models. Another major drawback is that drugs that work successfully on animals, fail to perform on humans later.

In order to counter the ever-pervasive issues in drug delivery, new biotechnologies are introduced. New biotechnologies can resemble and perform like human stem cells are deemed as successful alternatives to animal models. These structures are made from a combination of AI and microchips in the form of cell culture and organoid assays that can be used for testbeds for drugs. These cell-based assays are revolutionizing drug development.

The Paradigm Disruption: A Transition from Traditional to Biotechnological

Medical experts and doctors have expressed their discontentment about the traditional methods of drug delivery. Imbued with several limitations, the traditional methods of drug delivery failed to act in long bandwidths. From the standpoint of sustainability and affordability, traditional plastic multi-well plates are turned into intelligent devices with multi-core processing power. These devices can be programmed and updated from time to time.

The ultimate goal is to disseminate cures for diseases, quickening the pace of delivery, thereby enhancing readiness. This can be labelled as a significant and imperative disruption of the traditional paradigm while maintaining cost-effectiveness and sustainability.